All Type of News
About 40 generic companies enters ‘Twynsta’ market
Generics of ‘Twynsta(telmisartan, amlodipine),’ a leading drug in the hypertension complex market, are getting ready to be released.
As Twynsta lost the exclusivity with the expiration of the PMS(post-marketing surve...
Hanmi Pharm signs anticancer technology export of KRW 1 trillion with GenentechHanmi Pharm announced conclusion of a license agreement for the development and commercialization of HM95573, a targeted therapy under development for Phase 1 clinical trials, w...
|
GE Healthcare establishes ‘APAC Fast Track Center’ in Song-do
GE Healthcare announced it selected Korea as a biopharmaceutical hub for the Asia Pacific(APAC) region and decided to accelerate growth of the Korean biopharmaceutical industry by establishing an educational institute...
Pfizer Pharmaceuticals Korea keeps current corporate organization without divisionPfizer Pharmaceuticals Korea announced a plan to keep the current single corporate system of ‘Pfizer Pharmaceuticals Korea.’
The company revealed the Pfizer Group’s result of d...
|
Focusing on lecture & consulting fees, admin. investigation be effective to find rebates?
Mentioned at the recent National Inspection, administrative investigation on multinational pharmaceutical companies will conducted on a basis of lecture and consulting fees. A part of the industry, however, has a skep...
“Clinical trials led by researchers with characteristic as donation have risks to violate Kim Young-Ran Law”
An argument was suggested that there is a chance for clinical trials led by researchers with the characteristics of donation to violate the Bribery Prohibition Law.
The Transparent Pharmaceutical Business Network hel...
Enforcement of Bribery Prohibition Law makes everyone call ‘Dutch-paying’
“I guess we should start to go out for dinner with people close.”
After enforcement of the Bribery Prohibition Law, a whole new day has started.
While people are having lunch and dinner within the limit of the law, ...
Champix generics’ attempt to launch early, challenged by 14 companies
After challenges have been made to the substance patent of the Pfizer’s antismoking treatment Champix, other 14 Korean companies participated in the attempt. Once they get successful in the challenge, Champix generics...
Zuellig, “Novartis is only former minority shareholder which already transferred shares back to us”
Zuellig Pharma Korea announced an official position about its relationship with Novartis, which was indicated at the Ministry of Health and Welfare’s National Inspection.
On the 29th, Zuellig announced “We found unt...
3-way competition among Boehringer, Astra & MSD over new antidiabetic complexes
In the Korean diabetes treatment market, a 3-way competition is expected among complexes in combination with DPP-4 and SGLT-2 inhibitors.
According to MSD, ‘ertugliflozin,’ a SGLT-2 inhibitor jointly being developed ...
